FDA approves new and updated indications for Merck’s temozolomide

The Food and Drug Administration has approved updated labeling for temozolomide, or Temodar, from Merck under Project Renewal, an Oncology Center of Excellence initiative aimed at updating labeling information for older oncology drugs to ensure information is clinically meaningful and scientifically up-to-date. “This is the second drug to receive a labeling update under this pilot program,” the agency stated.